Product How it works Pricing Blog FAQ About Contact
Immunitybio

Immunitybio (NASDAQ: IBRX) net income

Immunitybio reported a net loss of $351.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $413.6m. Earnings per share were −$0.38.

Immunitybio's best year of the last 10 was fiscal 2018. It reported a loss in 10 of those 10 years.

Net income, in millions of US dollars-120.82016-96.42017-96.22018-157.82019-221.92020-346.82021-416.62022-583.22023-413.62024-351.42025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025−$351.4m—−310.2%−$0.38
2024−$413.6m—−2,804.8%−$0.59
2023−$583.2m—−93,761.4%−$1.15
2022−$416.6m—−173,569.6%−$1.04
2021−$346.8m—−37,129.6%−$0.89
2020−$221.9m—−36,669.6%−$0.59
2019−$157.8m—−7,165.2%−$0.43
2018−$96.2m—−204,736.2%—
2017−$96.4m—−214,273.3%—
2016−$120.8m—−274,565.9%—

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Immunitybio net income compared with its sector

By net income for its latest fiscal year, Immunitybio ranks 456th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Immunitybio, −310.2%.

RankCompanyNet incomeNet margin
454thViridian Therapeutics−$342.6m−483.6%
455thXenon Pharmaceuticals−$345.9m−4,612.1%
456thImmunitybio−$351.4m−310.2%
457thArcus Biosciences−$353.0m−142.9%
458thJazz Pharmaceuticals−$356.1m−8.3%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of Immunitybio

How much did Immunitybio earn in fiscal 2025?
Immunitybio reported a net loss of $351.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $413.6m.
What are the earnings per share of Immunitybio?
They were −$0.38 in fiscal 2025, compared with −$0.59 in fiscal 2024.
Where does Immunitybio rank in its sector by net income?
It ranks 456th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for Immunitybio come from?
From the annual report (Form 10-K) that Immunitybio files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Immunitybio files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Immunitybio: the Immunitybio page · annual accounts · revenue · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.